NCT05459415

Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC

Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore the 2-year DFS (disease-free survival) rate and organ retention rate and to explore the ORR, PCR rate, 2y-OS， and quality of life of patients.

Detailed description

This study aims to explore the 2-year DFS (disease-free survival) rate and organ retention rate after AP chemotherapy combined with anti-PD-1 antibody neoadjuvant treatment for HPV negative operable locally advanced head and HNSCC, and to explore the ORR, PCR rate, 2y-OS, and quality of life of patients.

Conditions

• Squamous Cell Carcinoma of Head and Neck
• Neoadjuvant Therapy
• Resection Margin

Interventions

Type	Name	Description
PROCEDURE	Reducing Excision Margins	Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy

Timeline

• Start date: 2022-06-22
• Primary completion: 2025-06-21
• Completion: 2027-06-21
• First posted: 2022-07-15
• Last updated: 2022-07-15

Locations

1 site across 1 country: China